Table 1 Calculated IC50 values in μM from broad and specific inhibitors of PRL phosphatase activity.

From: A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)

 

PRL-1

PRL-2

PRL-3

Broad PRL inhibitors

Candesartan

69 ± 8

80 ± 15

28 ± 4

Closantel

17 ± 3

14 ± 5

11 ± 0.5

Closantel Sodium

22 ± 8

18 ± 1

10 ± 0.4

Hexachlorophene

31 ± 4

35 ± 10

13 ± 1

Idasanutlin

20 ± 3

16 ± 2

13 ± 0.4

Napabucasin

0.4 ± 0.2

1.1 ± 0.3

0.7 ± 0.1

Salirasib

53 ± 5

118 ± 22

27 ± 3

Vitamin B12

0.7 ± 0.2

0.9 ± 0.2

0.9 ± 0.1

YM155

0.3 ± 0.1

0.7 ± 0.1

0.3 ± 0.1

PRL-3 specific inhibitors

Bardoxolone

85 ± 43

136 ± 75

24 ± 5*

Bithionol

79 ± 25

115 ± 34

33 ± 2*

Docusate Sodium

94 ± 26

140 ± 44

43 ± 5*

Eltromobag

56 ± 10

105 ± 19

26 ± 11*

Eltromobag Olamine

61 ± 15

166 ± 22

27 ± 4*

Embelin

114 ± 16

124 ± 60

52 ± 9*

  1. *p < 0.05 between IC50 values for PRL-3 and PRL-1 and PRL-2 by one-way ANOVA with Tukey’s HSD.
Back to article page